Search Results - "Mundayat, R"

THAOS – The Transthyretin Amyloidosis Outcomes Survey – Report on the patient demographic and baseline characteristics after 7 years of initiation by Barroso, F, Waddington-Cruz, M, Mundayat, R, Ong, M.L

Get full text

An overview of the demography, clinical characteristics and genetics of Latin America patients enrolled in THAOS by Waddington-Cruz, M, Barroso, F, González-Duarte, A, Mundayat, R, Ong, M.L

Get full text

Survival Following Heart Transplantation in Patients with Transthyretin Amyloid Cardiomyopathy by Selby, V.N, Mundayat, R, Maurer, M.S, Stern, L, Klein, L, Janmohamed, M, Kobashigawa, J.A, Kobes, R.D, De Marco, T

Get full text

0131 Survival & safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment: A number needed to treat analysis based on the intergroup exemestane study (IES) by Kilburn, L.S, Mundayat, R, Bliss, J.M, Coombes, C, Chirgwin, J, Chen, C, Fallowfield, L, Wang, Z

Get full text

Assessing the onset and characteristics of orthostatic hypotension in patients with transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) by Gonzalez-Duarte, A., Mundayat, R., Shapiro, B.

Get full text

The demographic, genetic, and clinical characteristics of asian subjects enrolled in the transthyretin amyloidosis outcomes survey (THAOS) by Waddington Cruz, M., Sekijima, Y., Mundayat, R.

Get full text

9143 Health-related quality of life (HRQOL) with sunitinib (SU) as maintenance therapy following carboplatin (C) and paclitaxel (P) treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) by Page, R, Blais, N, Torigoe, Y, Mundayat, R, Ball, G, Cappelleri, J.C, Kim, S.T, Chao, R, Goss, G

Get full text

P336A descriptive analysis of patients with wild-type ATTR cardiomyopathy from the transthyretin amyloidosis outcomes survey by Garcia-Pavia, P, Grogan, M, Dispenzieri, A, Mundayat, R, Amass, L, Rapezzi, C

“…Abstract Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disorder caused by the deposition of amyloid fibrils composed of…”
Get full text

Late-Onset Tranthyretin Familial Amyloid Polyneuropathy: Characterization of Brazilian Subjects from the THAOS registry by Waddington Cruz, M., Berensztejn, A., Pinto, M., Mundayat, R.

Get full text

P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years by Taxonera, C, Ha, C, del Pilar Fortes, M, Gardiner, S, Mundayat, R, Ghosh, S, Connor, S J

“…Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of…”
Get full text

P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open by Biedermann, L, Dubinsky, M C, Vermeire, S, Fellmann, M, Gardiner, S, Hur, P, Mundayat, R, Panés, J, Rubin, D T

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Tofacitinib induction and maintenance…”
Get full text

P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme by Sands, B E, Cohen, R D, Ha, C, Reinisch, W, Salese, L, Mundayat, R, Lawendy, N, Panés, J

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of…”
Get full text

THAOS – The Transthyretin Amyloidosis Outcomes Survey – Report on the patient demographic and baseline characteristics after 7years of initiation by Barroso, F., Waddington-Cruz, M., Mundayat, R., Ong, M.L.

Get full text

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open by Allegretti, J R, Gecse, K B, Chiorean, M V, Argollo, M, Guo, X, Lawendy, N, Su, C, Mundayat, R, Paulissen, J, Salese, L, Irving, P M

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Patients may require retreatment…”
Get full text

OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials by Sandborn, W J, D’Haens, G R, Sands, B E, Panaccione, R, Ng, S C, Lawendy, N, Kulisek, N, Guo, X, Mundayat, R, Su, C, Panés, J

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were…”
Get full text

P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme by Rubin, D T, Torres, J, Regueiro, M, Reinisch, W, Prideaux, L, Kotze, P G, Tan, F H, Gardiner, S, Mundayat, R, Cadatal, M J, Ng, S C

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were…”
Get full text

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open by Allegretti, J R, Gecse, K B, Chiorean, M V, Argollo, M, Guo, X, Lawendy, N, Su, C, Mundayat, R, Paulissen, J, Salese, L, Irving, P M

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In the tofacitinib UC clinical…”
Get full text

A multinational population survey of intravaginal ejaculation latency time by Waldinger, Marcel D, Quinn, Paul, Dilleen, Maria, Mundayat, Rajiv, Schweitzer, Dave H, Boolell, Mitradev

“…Intravaginal ejaculation latency time (IELT), defined as the time between the start of vaginal intromission and the start of intravaginal ejaculation, is…”
Get full text

P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme by Ungaro, R C, Ciorba, M A, Rogler, G, Sharara, A I, Sunna, N, Connelly, S B, Mundayat, R, Lawendy, N, Panés, J

“…Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). We present an updated analysis of…”
Get full text

P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib by Sandborn, W J, Gisbert, J P, Modesto, I, Su, C, Quirk, D, Mundayat, R, Guo, X, Chiorean, M, Reinisch, W

“…Abstract Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib in…”
Get full text